IL-11 Inhibitors – The Anti-Aging Breakthrough That Extended Lifespan by 25%

A Protein That Accelerates Aging

For decades, researchers have understood that chronic inflammation plays a central role in aging. But pinpointing exactly which inflammatory signals matter most—and whether we can safely block them—has proven enormously challenging. Now, a single protein has emerged as a particularly compelling target.

Interleukin-11, or IL-11, is a pro-inflammatory cytokine that belongs to the IL-6 family of signaling molecules. While it serves legitimate functions in wound healing and immune response, researchers have discovered something troubling: as mammals age, IL-11 levels increase dramatically across virtually every tissue type.

This wasn’t always considered a problem. For years, IL-11 was viewed as relatively benign compared to its more inflammatory cousins. But a landmark study published in Nature in July 2024 by researchers at Imperial College London, the MRC Laboratory of Medical Sciences, and Duke-NUS Medical School in Singapore fundamentally changed that understanding.

The research team, led by Professor Stuart Cook, found that elevated IL-11 doesn’t just correlate with aging—it actively drives many of the pathological changes we associate with getting older.

The Study That Changed Everything

The researchers approached the question from two directions. First, they genetically deleted the IL-11 gene in mice to see what would happen over a lifetime. Second, they treated aging mice with antibodies that neutralize IL-11 protein to determine whether blocking it later in life could still provide benefits.

The results exceeded expectations.

Mice with the IL-11 gene deleted lived an average of 24.9% longer than normal mice. Their median lifespan increased from 121 weeks to 151 weeks—a difference of roughly seven months in mouse terms.

Even more impressive were the results from antibody treatment. When researchers began treating mice at 75 weeks of age (equivalent to roughly 55 human years) with anti-IL-11 antibodies, the animals’ median lifespan extended by 22.5% in males and 25% in females. This is particularly significant because it suggests that intervention later in life can still produce meaningful benefits.

But longevity alone doesn’t tell the whole story. What matters equally is healthspan—the period of life spent in good health. Here, the IL-11 blocking intervention delivered remarkable improvements across multiple systems.

Beyond Living Longer: Living Better

The treated mice didn’t just survive longer; they thrived. The research documented improvements in virtually every metric of healthy aging.

Metabolic function improved significantly. Treated mice showed enhanced glucose tolerance and insulin sensitivity—key markers that typically deteriorate with age and contribute to type 2 diabetes risk. They accumulated less visceral fat, the dangerous type that surrounds internal organs and drives inflammatory disease.

Muscle function, which normally declines precipitously with age, remained robust. The mice maintained greater strength and endurance compared to untreated animals of the same age.

At the cellular level, several hallmarks of aging were reduced. Levels of pro-inflammatory cytokines decreased. Telomere length—the protective caps on chromosomes that shorten with age—was better preserved. Tissue fibrosis, the scarring that progressively impairs organ function, was reduced across multiple organs.

Perhaps most striking was the reduction in cancer incidence. Cancer is fundamentally a disease of aging, and the treated mice showed a marked decrease in tumor development. This aligns with growing evidence that chronic inflammation creates a permissive environment for cancer growth.

The Molecular Mechanism

Understanding why IL-11 blocking works requires examining the molecular pathways it affects. IL-11 operates through several interconnected signaling cascades that sit at the intersection of metabolism, growth, and cellular maintenance.

When IL-11 binds to its receptor, it activates ERK signaling—a pathway associated with cellular stress and senescence. It also suppresses AMPK, a master regulator of cellular energy that typically promotes longevity when activated. Additionally, IL-11 activates mTORC1, a growth-promoting pathway that, when chronically elevated, accelerates aging.

By blocking IL-11, researchers essentially reverse these effects: ERK activation decreases, AMPK activity increases, and mTORC1 calms down. This creates a cellular environment more conducive to maintenance and repair rather than stress and decline.

The fact that a single intervention can favorably modulate multiple aging pathways simultaneously is part of what makes IL-11 blocking so promising. Rather than targeting just one aspect of aging, it appears to address several fundamental drivers at once.

From Mice to Medicine

The most exciting aspect of this discovery is its potential for rapid translation to human medicine. Unlike many promising mouse studies that require developing entirely new drugs, IL-11 inhibitors already exist and are already in clinical testing.

In June 2025, Alphabet’s longevity-focused subsidiary Calico Life Sciences struck a licensing agreement with Shanghai-based Mabwell Bioscience for their IL-11 targeting antibody, 9MW3811. The deal included a $25 million upfront payment and up to $571 million in potential milestone payments—a significant bet on the antibody’s potential.

The antibody has already completed Phase I clinical trials in healthy volunteers in both Australia and China. The results demonstrated favorable safety and a half-life exceeding one month, meaning that infrequent dosing could provide sustained IL-11 suppression. In November 2025, the drug received approval to begin Phase II trials in China for pathological scarring.

While these current trials target specific diseases rather than aging itself, they provide crucial safety data. If the drug proves safe in humans across multiple indications, the path to testing its anti-aging effects becomes considerably shorter.

Several other companies are also developing IL-11 targeting therapies, creating competition that could accelerate progress. The fact that major players like Calico—backed by Alphabet’s resources—are investing heavily suggests genuine confidence in the approach.

Questions That Remain

Despite the promising results, important questions remain unanswered. Mouse studies, while valuable, don’t always translate to humans. Our longer lifespans, different physiology, and more complex disease patterns could produce different results.

The optimal timing and duration of treatment remain unclear. The mouse studies showed benefit from treatment starting at 75 weeks of age, but whether earlier or later intervention in humans would be more effective is unknown. Long-term safety of sustained IL-11 suppression in humans also needs evaluation—while the protein contributes to aging pathology, it does serve legitimate physiological functions.

The cost and accessibility of antibody therapies present practical challenges. Currently, monoclonal antibodies are expensive to produce and typically require injection, which could limit widespread adoption. Whether the benefits observed in mice will translate to meaningful healthspan extension in humans remains to be proven.

The Larger Landscape of Longevity Medicine

The IL-11 story represents a broader shift in how we approach aging. Rather than accepting decline as inevitable, researchers are identifying specific molecular drivers of aging that can potentially be modified.

IL-11 joins a growing list of targets that have shown lifespan-extending effects in animal studies, including rapamycin (which inhibits mTOR), senolytics (which clear senescent cells), and NAD+ precursors (which support cellular energy metabolism). Each targets different aspects of the aging process.

What distinguishes IL-11 blocking is the combination of effect size (25% lifespan extension is among the largest reported for a drug intervention), breadth of health benefits (affecting metabolism, muscle, inflammation, and cancer simultaneously), and translational potential (with drugs already in human testing).

The next few years will be critical. As clinical trials progress and safety data accumulates, we’ll learn whether this mouse discovery can fulfill its promise in humans. The scientific foundation is solid, the investment is flowing, and the drugs exist. What remains is the careful work of clinical validation.

The Path Forward

For those following longevity research, IL-11 inhibition represents one of the most actionable developments in recent years. It’s not a theoretical possibility or a distant future technology—it’s a therapeutic approach with drugs already in human trials and major pharmaceutical investment behind it.

The transition from laboratory discovery to clinical application typically takes many years, and there will undoubtedly be setbacks and surprises along the way. But the convergence of compelling basic science, existing drug candidates, and serious commercial interest creates genuine reason for measured optimism.

As the research continues to unfold, we may be witnessing the emergence of one of the first true anti-aging therapies—one that doesn’t just treat the diseases of aging, but addresses some of their fundamental causes.

Sources

1. Widjaja AA, et al. “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan.” Nature. July 2024. https://www.nature.com/articles/s41586-024-07701-9

2. MRC Laboratory of Medical Sciences. “Inhibiting IL-11 in mice extends healthy lifespan and reduces hallmarks of diseases associated with ageing.” July 2024. https://lms.mrc.ac.uk/inhibiting-il-11-in-mice-extends-healthy-lifespan-and-reduces-hallmarks-of-diseases-associated-with-ageing/

3. Calico Life Sciences Press Release. “Mabwell Bioscience and Calico Life Sciences Announce Exclusive Licensing Agreement for Novel IL-11 Targeting Monoclonal Antibody.” June 2025. https://www.calicolabs.com/press/mabwell-bioscience-and-calico-life-sciences-announce-exclusive-licensing-agreement-for-novel-il-11-targeting-monoclonal-antibody/

4. Fierce Biotech. “Alphabet’s Calico stitches $596M deal for Mabwell’s anti-aging asset.” June 2025. https://www.fiercebiotech.com/biotech/alphabets-calico-stitches-571m-deal-mabwells-anti-aging-asset

5. Mabwell Press Release. “9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring.” November 2025. https://www.prnewswire.com/news-releases/mabwells-novel-antiil11-monoclonal-antibody-9mw3811-approved-by-nmpa-to-initiate-phase-ii-clinical-trial-in-pathological-scarring-302611637.html